Clinicopathological correlation of invasive squamous cell carcinoma of uterine cervix: A cross-sectional study

Kalyani Raju¹,⁷, Raghuveer CV¹, Sheela SR²

ABSTRACT

Objective: Cervical cancer is a common cancer in females. Clinicopathological features vary and are heterogeneous in different studies. This study was taken up to know the clinicopathological correlation in squamous cell carcinoma (SCC) of the cervix in our population. Methods: This is a cross-section study. Histologically confirmed cases of squamous cell carcinoma of the cervix are considered. Clinical history, socio-demographic details, clinical findings including stage and histological grade of the disease are noted and statistically analyzed. Result: The age range of cases was 30-80 years, with a mean of 54.2±12.0. The age range at marriage was 12-23 years, with a mean of 15.7±2.1. Parity ranged from 1 to 11, with a mean of 3.6±1.6. The p-value between bleeding per-vagina and other symptoms versus no bleeding per-vagina and other symptoms, stage of disease between pre & peri-menopausal, and post-menopausal cases were 0.011 and 0.020, respectively. Growth followed by bleeding was common clinical findings. The p-value between the stage of the disease and age, histological grade and parity, histological grade and clinical features was 0.032, 0.001, and 0.031 respectively. Conclusion: Younger age group cases and pre & peri-menopausal women present the disease at an early stage. Older age women present at an advanced stage. Higher parity had a higher risk of cervical cancer of well differentiated SCC. Bleeding per-vagina was a more common clinical presentation in post-menopausal women. Clinical features of bleeding per-vagina with other symptoms were more common in well differentiated SCC.

Key words: cervical cancer, clinicopathological features, squamous cell carcinoma, uterine cervix

INTRODUCTION

Cervical cancer is a major health problem and is leading cancer in women, especially in developing regions of the world, resulting in mortality and morbidity in their prime reproductive age. The age standardized rates estimated are 30 per 100,000 women. However, the incidence and mortality are decreased by 75 to 80% by a well programmed screening procedure in developed countries. Pap test for screening cervical cancer has tremendously decreased the incidence of cervical cancer. However, in developing countries, despite the existence of a screening procedure, the women present at the late stage of the disease with high mortality¹⁻⁴. The risk factors are early marriage, early age of first sexual intercourse, early age of first pregnancy, multiple pregnancies, increased parity, use of oral contraceptive pills, multiple sexual partners, low socioeconomic status with nutritional/vitamin deficiencies, poor genital hygiene especially penile hygiene of a male partner, rural women, African-American race, tobacco smoking, sexually transmitted disease, Human Papilloma virus infection, Herpes Simplex virus infection, co-infection with HIV, immune compromised status especially in renal transplanted cases and genetic susceptibility²⁻⁵. In addition, lack of awareness of screening programmes, geographical inaccessibility, lack of an oncologist, negligence of initial symptoms along with financial constraints is responsible for a late presentation and diagnosis⁷⁻⁹. Clinicopathological studies are done and published in English literature. Clinicopathological features vary and are heterogeneous in different studies. Hence we have taken up this study to know the clinicopathological correlation in squamous cell carcinoma (SCC) of the cervix in our population.

MATERIAL AND METHODS

This is a cross sectional study done from October 2017 to September 2018. Ethical clearance for the study was obtained from the Institutional Ethical Committee. Clinically diagnosed and histopathologically confirmed 75 new cases of invasive SCC of the cervix were considered for the study. The exclusion criteria were Post-chemotherapy cases, post-radiotherapy cases, recurrence of the disease, cervical intraepithelial squamous neoplasia, glandular neoplasia, ade-
nocarcinoma of the cervix, metastatic deposits (secondary deposits) in the cervix. Following informed consent from the patients, the socio-demographic profile including clinical presentation and physical examination findings as: age, hospital number, biopsy number, presenting complaints, menstrual history, personal history, past history, family history, per-abdominal examination findings, per-speculum examination findings, per-vaginal examination findings and per-rectal examination findings were noted in a semi-structured proforma. The clinical stage and histological grade of the disease were also noted. The staging was done as per the FIGO staging system. Histologically the cases were classified as keratinizing and non-keratinizing types. Keratinizing squamous cell carcinomas were further classified as well differentiated (WDSCC), moderately differentiated (MDSCC), and poorly differentiated (PDSCC). The non-keratinizing squamous cell carcinomas were further classified as small cell type (NKSCC) and large cell type (NKLCSCC). The data were entered in Microsoft Excel sheet. The data was analyzed using SPSS version 22. The categorical data were recorded as frequency and proportions. Continuous data was entered as mean, standard deviation, and confidence intervals. Significance of difference between the groups was estimated using standard ‘t’ test and chi-square test, p-value <0.05 was considered as statistically significant.

**Table 1: Shows the age distribution in cases in the present study**

| Age range (years) | Cases  |
|------------------|--------|
| 30-39            | 8 (10.6%) |
| 40-49            | 19 (25.3%) |
| 50-59            | 18 (24%) |
| 60-69            | 19 (25.3%) |
| 70-79            | 10 (13.3%) |
| 80-89            | 1 (1.3%) |
| Total            | 75 (100%) |

**Table 2: Shows the age in years at menopause among cases in the present study**

| Age in years at menopause | No of cases |
|---------------------------|-------------|
| Pre & Peri-menopausal     | 19 (25.3%)  |
| 40-44                     | 16 (21.3%)  |
| 45-49                     | 25 (33.3%)  |
| 50-54                     | 13 (17.3%)  |
| 55-59                     | 2 (2.6%)    |
| Total                     | 75 (100%)   |

**Table 3: Shows the age in years at marriage among cases in the present study**

| Age at marriage (years) | No of cases (%) |
|-------------------------|-----------------|
| 12                      | 5 (6.6%)        |
| 13                      | 2 (2.6%)        |
| 14                      | 12 (16%)        |
| 15                      | 20 (26.6%)      |
| 16                      | 11 (14.6%)      |
| 17                      | 10 (13.3%)      |
| 18                      | 11 (14.6%)      |
| 19                      | 1 (1.3%)        |
| 20                      | 1 (1.3%)        |
| 22                      | 1 (1.3%)        |
| 23                      | 1 (1.3%)        |
| Total                   | 75 (100%)       |

**Table 4: Shows the parity among cases in the present study**

| Para | No. of cases |
|------|--------------|
| Para 1 | 6 (8%)      |
| Para 2 | 11 (14.6%)  |
| Para 3 | 17 (22.6%)  |
| Para 4 | 20 (26.6%)  |
| Para ≥5 | 21 (28%)    |
| Total  | 75 (100%)    |

**RESULTS**

The age distribution of the cases is shown in Table 1. The age range was 30-80 years of age, with a mean age of 54.2±12.0. Maximum cases were seen in the age group of 40-49 and 60-69 years (25.3%)
followed by 50-59 years (24%). 74.7% of cases were postmenopausal, and 25.3% of cases were pre and peri-menopausal groups. Table 2 shows the age at menopause among the cases where the majority of females had attained menopause between 45-49 years (33.3%) of age group followed by 40-44 years (21.3%). The age range was 40-57 years, with a mean of 46.3±3.9 years. Table 3 shows age at marriage among the cases where maximum cases were at 15 years (26.6%) followed by 14 years (16%) of age. The age range was 12-23 years, with a mean of 15.7±2.1 years of age. Table 4 shows the parity in cases where maximum cases had parity of ≥5 (28%) followed by 4 (26.6%). Parity ranged from a 1-11 with a mean of 3.6±1.6.

Table 5 shows the varied clinical presentation in cases among pre & peri-menopausal and post-menopausal women. The P-value for bleeding per-vagina and other symptoms versus no bleeding per-vagina and other symptoms between pre & peri-menopausal and post-menopausal cases was 0.011. In pre & peri-menopausal, women bleeding per-vagina and white discharge per vagina were approximately equally seen. Table 6 shows per-speculum findings of cases, among pre & peri-menopausal and post-menopausal women. Growth followed by bleeding is the common findings of cases, among pre & peri-menopausal and post-menopausal cases was 0.760. Table 7 shows per-vaginal findings of cases, among pre & peri-menopausal and post-menopausal women. The P-value for per-speculum findings between pre & peri-menopausal and post-menopausal cases was 0.760. Table 8 shows the stages of the disease in cases in both pre & peri-menopausal and post-menopausal women. Maximum cases were seen in stage IV (21.3%). The P-value of stage of disease between pre & peri-menopausal and post-menopausal cases was 0.46.

There was a statistically significant association between the stage of the disease and the age of the cases with a p-value of 0.032. However, there was no statistically significant association between the stage of the disease with age at marriage (p=0.259), parity (p=0.752), clinical features (p=0.334) and per-speculum examination findings (p=0.295).

There was a statistically significant association between the histological grade of the disease with parity of the cases (p<0.001) and clinical features of the disease (p=0.031). However, there was no statistically significant association between histological grade and age of cases (p=0.132), age at marriage (p=0.578), and per-speculum examination findings (p=0.629).

**DISCUSSION**

Globally 13% of all deaths are due to cancer. Cervical cancer constitutes 5th deadliest cancer worldwide, causing 5% of cancer death in females. It was leading cancer in women 50 years back and has decreased because of screening programmes which detect precancerous lesions and malignancy in the early stage. Annually the incidence is approximately 510,000 cases, with 288,000 deaths worldwide. 80% of cases are recorded in developing countries. It occurs in 16 per 1000 women causing 9 per 1000 deaths in developing countries and accounts for 1.7 million cases. India accounts for 1/5th of the world’s cervical cancer cases, with 134,000 cases and 72,825 deaths. In NICRH Dhaka, Bangladesh, 19.2% of women cancer constituted cervical cancer. In a study at a tertiary health care center in South India, cervical cancer constituted 17% of female cancers. Cervical cancer constituted 78.44% of all cancers of the female genital tract and 12.94% of all lesions of the cervix.

Screening by Pap test has reduced the incidence and prevalence of cervical cancer. Screening every 5 and 3 years prevents cervical cancer by 84% and 91%, respectively. WHO predicts that by 2030, approximately 98% of cervical cancer deaths will be reported from developing countries.

Among the cervical cancer cases, Illiterates who can only sign were 50.7% and with primary education were 41.8%. The percentage of women who were married, divorced, and widow was 74.6%, 3%, and 19.4%, respectively. In a study, Jain DK et al., the illiterates were 97% and with primary education 3%. Amaro-Filho SM et al., in their study, states that advanced stage (stage III & IV) shows the significant statistical association (p<0.005) with no formal education.

In the present study illiterates were 90.6%, and those with primary education were 10.4%. The mean age reported by Afroj et al. is 44.9±12.01 years, with the age range of 20-75 years. In a study by Jain DK et al., the age range was 40-70 years of age.
**Table 5:** Shows varied clinical presentation of cases in the present study

| Clinical Presentation       | Total no of cases presented n=75 (%) | Pre & Peri-menopausal cases n=19 (%) | Post-menopausal cases n=56 (%) |
|----------------------------|--------------------------------------|---------------------------------------|--------------------------------|
| Bleeding per vagina        | 60 (80%)                             | 13 (68.2%)                            | 47 (83.9%)                     |
| WDPV                       | 51 (68%)                             | 10 (52.6%)                            | 41 (73.2%)                     |
| Others                     | 48 (64%)                             | 11 (57.8%)                            | 37 (66.0%)                     |
| Pain Abdomen               | 40 (53.3%)                           | 12 (63.1%)                            | 28 (50.0%)                     |
| Post-coital bleeding       | 4 (5.3%)                             | 1 (5.2%)                              | 3 (5.3%)                       |
| Mass per vagina            | 2 (2.6%)                             | 1 (5.2%)                              | 1 (1.7%)                       |
| No symptoms                | 2 (2.6%)                             | 2 (10.5%)                             | –                              |

WDPV: White discharge per vagina

**Table 6:** Shows per-speculum findings of cases in the present study

| Per-speculum findings   | Total No. of cases | Pre & Peri-menopausal cases | Post-menopausal cases |
|-------------------------|--------------------|-----------------------------|-----------------------|
| Growth                  | 49 (65.3%)         | 11 (57.8%)                  | 38 (67.8%)            |
| Bleeding                | 8 (10.6%)          | 2 (10.5%)                   | 6 (10.7%)             |
| Erosion                 | 6 (8%)             | 3 (15.7%)                   | 3 (5.3%)              |
| Ulcer                   | 5 (6.6%)           | 2 (10.5%)                   | 3 (5.3%)              |
| Unhealthy               | 3 (4%)             | 1 (5.2%)                    | 2 (3.5%)              |
| Mass                    | 2 (2.6%)           | 00                          | 2 (3.5%)              |
| Stenosis                | 1 (1.3%)           | 00                          | 1 (1.7%)              |
| WDPV                    | 1 (1.3%)           | 00                          | 1 (1.7%)              |
| Total                   | 75 (100%)          | 19 (100%)                   | 56 (100%)             |

WDPV: White discharge per vagina

**Table 7:** Shows per-vaginal findings of cases in the present study

| Per vaginal examination  | Total No. of cases | Pre & Peri-menopausal cases | Post-menopausal cases |
|--------------------------|--------------------|-----------------------------|-----------------------|
| Friable Growth           | 45 (60.0%)         | 11 (57.8%)                  | 34 (60.7%)            |
| Induration               | 28 (37.3%)         | 7 (36.8%)                   | 21 (37.5%)            |
| Erosion                  | 1 (1.3%)           | 00                          | 1 (1.7%)              |
| Stenosis                 | 1 (1.3%)           | 1 (5.2%)                    | 00                    |
| Total                    | 75 (100%)          | 19 (100%)                   | 56 (100%)             |

**Table 8:** Shows stages of the disease in cases in the present study

| Stage of the disease    | Total No of cases | Pre & Peri-menopausal cases | Post-menopausal cases |
|-------------------------|-------------------|-----------------------------|-----------------------|
| Stage I                 | 6 (8%)            | 4 (21.0%)                   | 2 (3.5%)              |
| Stage II                | 24 (32%)          | 7 (36.8%)                   | 17 (30.5%)            |
| Stage III               | 30 (40%)          | 3 (15.7%)                   | 27 (48.2%)            |
| Stage IV                | 15 (20%)          | 5 (26.3%)                   | 10 (17.8%)            |
| Total                   | 75 (100%)         | 19 (100%)                   | 56 (100%)             |
Table 9: Shows histological grade of the disease in cases in the present study

| Grade of the disease | No of cases (%) | Pre & Peri-menopausal cases | Post-menopausal cases |
|----------------------|-----------------|-----------------------------|-----------------------|
| WDSCC                | 42 (56%)        | 13 (68.4%)                  | 29 (51.7%)            |
| MDSCC                | 16 (21.3%)      | 3 (15.7%)                   | 13 (23.2%)            |
| PDSCC                | 10 (13.3%)      | 1 (5.2%)                    | 09 (16.1%)            |
| NKLCSCC              | 5 (6.6%)        | 2 (10.5%)                   | 3 (5.3%)              |
| NKSCSCC              | 2 (2.6%)        | –                           | 2 (3.5%)              |
| Total                | 75 (100%)       | 19 (100%)                   | 56 (100%)             |

WDSCC: Well differentiated squamous cell carcinoma
MDSCC: Moderately differentiated squamous cell carcinoma
PDSCC: Poorly differentiated squamous cell carcinoma
NKLCSCC: Non-keratinizing large cell squamous cell carcinoma
NKSCSCC: Non-keratinizing small cell squamous cell carcinoma

Table 10: Shows the age distribution in various studies compared to the present study

| Age range (years) | Patil et al., 2019 | Gundrakuppam et al., 2011 | Sarwath et al., 2017 | Afroj et al., 2017 | Gaikwad et al., 2016 | Present study, 2019 |
|-------------------|--------------------|--------------------------|---------------------|-------------------|---------------------|---------------------|
| 20-29             | 8.6%               | 5.2%                     | 18.6%               | 9%                | 6.5%                | –                   |
| 30-39             |                    | 37.3%                    | 13.1%               | 10.6%             |                     |                     |
| 40-49             | 65.3%              | 60.5%                    | 51.4%               | 26.9%             | 27.6%               | 25.3%               |
| 50-59             |                    |                          | 20.9%               | 32.8%             | 24%                 |                     |
| 60-69             | 26%                | 34.2%                    | 30.0%               | 6%                | 22.3%               | 25.3%               |
| 70-79             | –                  |                          |                     |                   |                     | 13.3%               |
| 80-89             | –                  |                          |                     |                   |                     | 1.3%                |

Table 11: Shows the parity in various studies compared with the present study

| Para              | Patil et al., 2019 | Afroj et al., 2017 | Jain et al., 2017 | Present study, 2019 |
|-------------------|--------------------|-------------------|-------------------|---------------------|
| Para 1            | 46%                | 20.9%             | 48%               | 8%                  |
| Para 2            |                    |                   |                   | 14.6%               |
| Para 3            |                    |                   |                   | 22.6%               |
| Para 4            | 53.9%              |                   |                   | 26.6%               |
| Para ≥5           | 79.1%              | 52%               |                   | 28%                 |

with 87% of cases in more than 40 years of age and a mean age of 56.17 years. In a study by Esmeaili et al., the mean age of cervical cancer was 52 years with two peaks, one at 35-39 years and others at 60-64 years of age. In a study by Stoler et al., the mean age of cervical cancer was 41.0 years. Advanced age is a risk factor. Postmenopausal bleeding is the most characteristic symptom in carcinoma cervix. Hence cervical cancer should be suspected in cases of bleeding per vagina in old age. Amaro-Filho SM et al., in their study, states that advanced stage (stage III & IV) shows the significant statistical association (p<0.005) with the advanced age of more than 55 years of age. In the present study, the age range was 30-80 years of age, with a mean age of 54.2±12.0. There was a statistically significant association between age and stage of the disease (p=0.032), indicating younger age group cases presented with early stage and older age group presented with a late stage of the disease. There was statistical significant association between the stage of disease versus pre & peri-menopausal and post-menopausal cases (p=0.020) indicating that pre & peri-menopausal women present the disease in a relatively early stage compared to post-menopausal who present in late stage of the disease probably because of atrophied cervix and relatively less volume.
### Table 12: Shows the clinical presentation in various studies compared with the present study

| Clinical Presentation | Patil et al., 2019⁵ | Gundrajakuppam et al., 2011⁸ | Afroj et al., 201⁹ | Gaikwad et al., 201⁶¹² | Jain et al., 201⁷⁷ | Present study, 201⁹ |
|-----------------------|---------------------|-------------------------------|-------------------|------------------------|------------------|------------------|
| Bleeding per vagina   | 53.3%               | 21.0%                         | 80.5%             | 69.7%                  | 65%              | 80%              |
| Post-menopausal bleeding | 16%               | 28.9%                         | –                 | –                     | 65%              | 85.7%            |
| WDPV                  | 64%                 | 44.7%                         | 67.1%             | 39.4%                  | 72%              | 68%              |
| Pain Abdomen          | –                   | 0%                            | –                 | 19.7%                  | 28%              | 53.3%            |
| Post-coital bleeding  | 22.6%               | –                             | 86.5%             | 11.8%                  | –                | 5.3%             |
| Mass per vagina       | 0.6%                | 2.6%                          | –                 | 3.9%                   | 13%              | 2.6%             |
| Others                | 66.6%               | 2.6%                          | –                 | 14.4%                  | 83%              | 64%              |
| No symptoms           | –                   | 2.3%                          | –                 | –                      | –                | 2.6%             |

WDPV: White discharge per vagina

### Table 13: Shows Per-Speculum examination findings in various studies compared with the present study

| Per-speculum findings | Gundrajakuppam et al., 2011⁸ | Jain et al., 201⁷⁷ | Present study, 201⁹ |
|-----------------------|-------------------------------|-------------------|------------------|
| Growth               | 81.5%                         | 02%               | 65.3%            |
| Bleeding             | –                             | –                 | 10.6%            |
| Erosion              | 5.2%                          | –                 | 8%               |
| Ulcer                | 2.6%                          | 72%               | 6.6%             |
| Unhealthy            | –                             | –                 | 4%               |
| Mass                 | –                             | –                 | 2.6%             |
| Stenosis             | –                             | –                 | 1.3%             |
| WDPV                 | –                             | –                 | 1.3%             |
| Others               | 7.8%                          | 19%               | –                |
| Normal               | 2.6%                          | 07%               | –                |

WDPV: White discharge per vagina

### Table 14: Shows the stage of the disease in cases in various studies compared with the present study

| Stage of the disease | Patil et al., 201⁹⁵ | Afroj et al., 201⁹⁹ | Jain et al., 201⁷⁷ | Goellner, 1976¹³ | Present study, 201⁹ |
|----------------------|---------------------|---------------------|-------------------|-----------------|------------------|
| Stage I              | 4.6%                | 18.96%              | –                 | 42.4%           | 8%               |
| Stage II             | 26.6%               | 44.81%              | 80%               | 41.4%           | 32%              |
| Stage III            | 65.3%               | 34.47%              | 20%               | 11.7%           | 40%              |
| Stage IV             | 33.3%               | 1.72%               | –                 | 4.6%            | 20%              |
Table 15: Shows histological type of the disease in cases in various studies compared with the present study

| Grade of the disease | Patil et al., 2019 | Gaikwad et al., 2016 | Jain et al., 2017 | Present study, 2019 |
|----------------------|-------------------|----------------------|------------------|---------------------|
| WDSCC                | 22.2%             | 11.84%               | 62.7%            | 56%                 |
| MDSCC                | 61.1%             | 71.05%               | 26.3%            | 21.3%               |
| PDSCC                | 16.6%             | 17.11%               | 1.8%             | 13.3%               |
| NKLCSCC              | –                 | –                    | 7%               | 6.6%                |
| NKSCSCC              | –                 | –                    | 2.6%             |                     |

WDSCC: Well differentiated squamous cell carcinoma  
MDSCC: Moderately differentiated squamous cell carcinoma  
PDSCC: Poorly differentiated squamous cell carcinoma  
NKLCSCC: Non-keratinizing large cell squamous cell carcinoma  
NKSCSCC: Non-keratinizing small cell squamous cell carcinoma

of healthy cervical tissue resulting in fast spread of the disease. Hence younger patients and patients in the pre & peri-menopausal age group presented at an early stage in the present study. There was no statistical association between age and histological grade of the disease in the present study. The age distribution in various studies compared to the present study is shown in Table 10, where maximum cases are seen between 40-59 years of age in all studies.

Early marriage is a risk factor as frank cases with late stage of the disease is noted when the age of marriage was between 15-19 years followed by 20-24 years. Age at the marriage of fewer than 20 years was 49.25% of cases in a study by Afroj et al. 1983% and 17% of cases had first coitus at less than or equal to 20 years and more than 20 years, respectively, in a study by Jain et al.7, Amaro-Filho SM et al., in their study, states that the advanced stage was also associated with the age of marriage at less than 17 years but not statistically significant (p=0.752)14. Cervical carcinoma behaves as a sexually transmitted disease8. There was no statistical association between age at marriage in cases with stage and histological grade of the disease in the present study. The age range for marriage was 12-23 years, with mean 15.7±2.1 years of age. Maximum cases were between 15-18 years (69.3%), followed by 12-14 years (25.3%). Among cases between 15-18 years, 59.6% of cases were in the advanced stage. Frank cervical cancer with the late stage was seen maximum with parity of ≥4 followed by 3 in a study by Patil N et al.5. Among cases, 3.8% were nulliparous, and 96.2% were multiparous in a study by Jyothi V et al.16. Amaro-Filho SM et al., in their study, states that advanced stage (stage III & IV) shows a significant statistical association (p<0.005) with more than four pregnancies14. In the present study, parity ranged from 1 to 11, with a mean of 3.6±1.6. There was no statistically significant association between parity and stage of the disease in the present study. However, 55% of para 4 cases and 66.6% of para ≥5 were in an advanced stage (stage III & IV). There was a statistically significant correlation between parity and histological grade of the disease (p=0.001) which indicates that higher parity had a higher risk of cervical cancer of WDSCC followed the MDSCC histological type. The parity in various studies compared with the present study is shown in Table 11, where maximum cases are seen with parity ≥4 in all studies.

Patients of cervical cancer present with local and systemic symptoms. The local symptoms can be bleeding per vagina, mass per vagina, rarely leakage of urine, or feces per vagina. The systemic symptoms are loss of appetite, loss of weight, weakness, pelvic pain, pain in the leg, etc.5. Irregular bleeding per vagina had a statistical association with stages of cancer7. In the present study, there was a significant association between bleeding per-vagina and other symptoms versus no bleeding per-vagina and other symptoms between pre & peri-menopausal and post-menopausal cases (p=0.011) which indicates that bleeding per-vagina was a more common clinical presentation in post-menopausal women than in pre & peri-menopausal which can be due to atrophic cervix and age-related changes of blood vessels. There was also a statistical association between clinical presentation and histological grade of the disease (p=0.031) suggesting that the clinical features of bleeding per vagina with other symptoms were more common in WDSCC, followed by MDSCC than in cases without bleeding per vagina. In the present study, there was no statistical association between clinical presentation and stage of the disease. The clinical presentation in cases in various studies compared with the present study is shown in Table 12, where bleeding...
per-vagina is the most frequent presentation in the present study and study by Gaikwad et al. WDPV was the most frequent presentation in a study by Patil et al., Gundrajakuppam et al., and Jain et al. The most frequent finding was ulcer (72%) in the present study. The commonest per-vaginal examination findings reported is frank growth, which bleeds on touch. Cervical growth was noted in 9.2% of cases in a study by Gaikwad SL et al. In the present study, growth which bleeds on touch was the commonest presentation. There was no significant association between per-spectrum findings with stage and histological grade of the disease.

Table 13 shows the stage of the disease in cases in various studies compared with the present study, where stage I was commonest in the study by Goellner. Stage II was commonest in the study by Afroj et al. and Jain et al. Stage III was commonest in the study by Patil et al. and the present study. Table 14 shows the histological type of the disease in cases in various studies compared with the present study where WDSCC is commonest in the present study and study by Afroj et al. MDSCC was commonest in the study by Patil et al. and Gaikwad et al. 44.44% of all the cervical biopsies were squamous cell carcinoma in a study by Jyothi V et al. Among cervical cancer, 80-90% of cervical cancer are squamous cell carcinoma and 14% adenocarcinoma, as reported by Patil N et al. Squamous cell carcinoma constituted 86.57% and adenocarcinoma 13.43% in a study by Afroj S et al. Squamous cell carcinoma constituted 95% of the cases of cervical carcinoma in a study by Patil et al. 91% of cases were squamous cell carcinoma, and 9% were adenocarcinoma in a study by Jain DK et al. Of squamous cell carcinoma, 91% were keratinizing type, 07% were non-keratinizing type, and 02% were basaloïd type. In a study by Sarwath et al., histological type analysis showed 26% were keratinizing and 68.8% non-keratinizing type. In a study by Goellner et al., keratinizing was 29.0%, and non-keratinizing was 71%. In the present study, the keratinizing and non-keratinizing types constituted 90.8% and 9.2%, respectively. There is no significant difference in the prognosis between histological types of tumors within any stage. However, large-cell cancers have a better prognosis than keratinizing cancers, and small-cell cancers have the worst prognosis. The stage of the disease has a definite impact on prognosis. In the present study, the cases were not followed up for prognosis. The limitation of the present study is that the cases were not followed up for prognosis. However a few objective conclusions were drawn by this study which can be generalized by doing a similar study in a larger population as; younger age group cases and pre & peri-menopausal women present the disease at an early stage compared to post-menopausal women, older age presents with advanced stage, maximum cases were seen between 15-18 years of age of marriage, higher parity had a higher risk of cervical cancer of WDSCC and advanced stage, bleeding per-vagina was a more common clinical presentation in post-menopausal women than in pre & peri-menopausal, a growth which bleeds on touch was the common clinical examination findings in both pre & peri-menopausal and post-menopausal, clinical features of bleeding per vagina with other symptoms were more common in WDSCC than cases without bleeding per vagina and other symptoms.

CONCLUSION

Cases with younger age present with early stages of cancer. Cervical cancer screening should be done in older age women more frequently, especially when the clinical feature is bleeding per vagina as they present with advanced stage. Young age at marriage and high parity are high risk factors for cervical cancer. WDSCC is associated with high parity and bleeding per vagina.

ABBREVIATIONS

FIGO: International Federation of Gynecology and Obstetrics
HIV: Human Immunodeficiency Virus
MDSCC: Moderately differentiated squamous cell carcinoma
NKLCSCC: Non-Keratinizing Large Cell squamous cell carcinoma
NKSCCSCC: Non-Keratinizing Small Cell squamous cell carcinoma
PDSCC: Poorly differentiated squamous cell carcinoma
SCC: squamous cell carcinoma
WHO: World Health Organisation
WDPV: White discharge per vagina
WDSCC: Well differentiated squamous cell carcinoma
COMPETING INTERESTS
We have no conflict of interest to declare.

AUTHORS’ CONTRIBUTIONS
Kalyani Raju: Concept, collection of data, review of literature, case collection, statistical analysis, drafting / editing / review of manuscript. Raghuveer CV: Concept, editing / review of manuscript. Sheela SR: Case collection, editing manuscript.

ACKNOWLEDGEMENTS
We acknowledge Dr Sunil Bhage, Assistant Professor of Community Medicine, Sri Devaraj Urs Medical College, Sri Devaraj Urs Academy of Higher Education and Research, Kolar. Karnataka, for contribution in statistical analysis.

REFERENCES
1. Sarwath H, Bansal D, Husain NE, Mohamed M, Sultan AA, Bedri S. Introduction of p16INK4a as a surrogate biomarker for HPV in women with invasive cervical cancer in Sudan. Infect Agent Cancer. 2017;12(1):50. PMID:29021820. Available from: 10.1186/s13027-017-0159-0.
2. Ahmed SA, Obaseki DE, Mayun AA, Mohammed A, Rafindadi AH, Abdul MA. The role of biomarkers (p16INK4a and Ki-67) in cervical cancer screening: an appraisal. Ann Trop Pathol. 2017;8(1):1–4. Available from: 10.4103/atp.atp_3_17.
3. Kalyani R, Das S, Bindia MJS, Kumar HM. Cancer profile in Kolar: A ten years study. Indian J Cancer. 2010;47(2):160–5. PMID: 20448380. Available from: 10.4103/0019-509X.63011.
4. Esmaeili HA, Pourlak T, Ghamari B, Shayan FK, Sanaat Z, Soltani GG, et al. Comparison of nuclear P16 immunostaining in atypical and normal endocervical glands: A descriptive analytical study. J Anal Res Clin Med. 2018;6(2):66–71. Available from: 10.15171/jarcrm.2018.010.
5. Patil N, Deshmukh V, Rathid A, Jyoti D, Chavan S. Clinicopathological Correlation of Cervical Carcinoma: A Tertiary Hospital-based Study. Int J Sci Stud. 2019;6(10):1–4.
6. Jyothi V, Manoja V, Reddy SK. A Clinicopathological Study on Cervix. Journal of Evolution of Medical and Dental Sciences. 2015;4(13):2100–6.
7. Jain DK, Shukla P, Gupta V. Clinicopathological Survey of Carcinoma Uterine Cervix In Patients Attending Tertiary Care Hospital Of Central Uttar Pradesh. Int J Sci Res (Ahmedabad). 2017;6(9):63–5.
8. Gundrajakuppam L, Vissa S, Nandam MR, Srerelam S, Majety DV, Kuppal P, et al.; 2011.
9. Afroz S, Banu MA, Sultana S, Jahan R, Rahman S, Begum N. Clinicopathological Profile of Cervical Cancer patients attending in a specialized Hospital. J Dhaka Med Coll. 2017;26(2):117–21. Available from: 10.3329/jdmc.v26i2.38826.
10. Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet. 2009;105(2):107–8. PMID: 19342051. Available from: 10.1016/j.ijgo.2009.02.009.
11. Stoler M, Bergeron C, Colgan TJ, Ferenczy AJS, Herrington CS, Kim KR, et al. Kurman RJ, Carcangin ML, Herrington CS, Young RH, editors. Squamous cell tumors and precursors. Lyon: International Agency for Research on Cancer; 2014.
12. Gaikwad SL, Valand AG, Agarwal NU. Clinicohistopathological analysis of lesions of uterine cervix in Ambejogai city of Maharashtra: A 2 year study at tertiary level hospital. Journal of Diagnostic Pathology and Oncology. 2016;12(2):32–5.
13. Goellner JR. Carcinoma of the cervix. Clinicopathologic correlation of 196 cases. Am J Clin Pathol. 1976;66(5):775–85. PMID: 98396. Available from: 10.1093/ajcp/66.5.775.
14. Amano-Filho SM, Golub JE, Nuovo GJ, Cunha CB, Levi JE, Villa LL, et al. A comparative analysis of clinical and molecular factors with the stage of cervical cancer in a Brazilian cohort. PLoS One. 2013;8(3):e57810. PMID: 23505442. Available from: 10.1371/journal.pone.0057810.
15. Stoler MH, Wright TC, Ferenczy A, Ranger-Moore J, Fang Q, Kapadia M, et al. Routine Use of Adjunctive p16 Immunohistochemistry Improves Diagnostic Agreement of Cervical Biopsy Interpretation: Results From the CERTAIN Study. Am J Surg Pathol. 2018;42(8):1001–9. PMID: 29697437. Available from: 10.1097/PAS.0000000000001072.